Anika Therapeutics Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Anika Therapeutics Inc's ROI in the third quarter of 2026?
Anika Therapeutics Inc recorded a cumulative net loss of $-2 million during 12 months ending in the third quarter of 2026, resulting in a negative return on investment (ROI) of -1.17%.

Within the Healthcare sector 108 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Sep 30 2026 quarter, so far to 2977, from total ROI ranking in the second quarter of 2026 at 3467.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Investment Change TTM	-0.01 %	-7.75 %	-18 %	-22.6 %	-27.15 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	163	161	134	143	147
Return On Investment (TTM)	-1.17 %	-2.59 %	-7.74 %	-7.42 %	-21.96 %
ANIK's Overall Ranking	# 2977	# 3467	# 3422	# 3695	# 3662
Seq. Investment Change TTM	2.74 %	2.39 %	-2.47 %	-2.54 %	-5.21 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-2	-4	-11	-11	-33

ANIK Company Profile >> Back to ANIK Roi Comparisons >> See Annual ANIK Return On Investment

Return On Investment ANIK's Ranking
Within:	No.
Industry	# 34
Sector	# 109
Overall	# 2977

Return On Investment Statistics
High	Average	Low
22.77 %	2.12 %	-41.94 %
(Jun 30 2014)		(Sep 30 2024)

Financial Statements
Anika Therapeutics Inc's III. Quarter Investments	$ 163 Millions	ANIK's Balance sheet
Anika Therapeutics Inc's III. Quarter Income	$ 0 Millions	Quarterly ANIK's Income Statement
ANIK's Income by Division		See ANIK's Income by Division

ANIK Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	143	155	212	286	318
Y / Y Investment Growth	-7.23 %	-27.14 %	-25.67 %	-10.13 %	-3.35 %
Net Income in Millions	-11	-56	-83	-15	4
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-7.58 %	-36.46 %	-38.95 %	-5.2 %	1.3 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Medical Equipment & Supplies Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ANIK's Roi Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ANIK's Competitors
Subscribers only: Roi for Anika Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for ANIK's Customers

Other Ratios
ANIK's Roa	ANIK's Inventory Turnover Ratio	ANIK's Growth Rates	ANIK's Dividend Statistics
	ANIK's Profitability Ratios	ANIK's Asset Turnover Ratio	ANIK's Dividend Growth
ANIK's Roe	ANIK's Valuation Ratios	ANIK's Financial Strength Ratios	ANIK's Dividend Payout Ratio

Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector

ROI

Date modified: 2026-11-08T13:37:57+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.